Retatrutide
The Most Powerful Metabolic Peptide in Research
$65.00 USD
Mechanism of Action
Retatrutide is a first-in-class triple hormone receptor agonist. Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide hits all three receptors: GLP-1 (appetite suppression, insulin sensitization), GIP (nutrient sensing, fat metabolism), and glucagon (lipolysis, thermogenesis, hepatic glucose regulation). This triple action creates a compounding metabolic effect that no single- or dual-agonist can match. Phase 2 clinical data showed the most significant weight reduction of any peptide studied to date.
What Researchers Report
- check_circle Up to 24% body weight reduction in 48-week clinical trial models.
- check_circle Superior glycemic control vs dual-agonist comparators.
- check_circle Significant reduction in hepatic fat content (liver health marker).
Researched For
Metabolic research, body composition optimization, appetite regulation, insulin sensitivity, and liver health studies. This is the next generation beyond semaglutide — researchers studying metabolic pathways consider this the most promising compound in the space.
Research Protocols
Common dosing schedules in literature
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| Titration Start | 1mg | 1x/week | 4 weeks |
| Mid Titration | 4mg | 1x/week | 4 weeks |
| Research Dose | 8-12mg | 1x/week | 12+ weeks |
For research reference only. Serenity does not recommend specific protocols.
Stack With
Researchers commonly pair Retatrutide with these compounds for enhanced protocols.
WARNING: THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.